Onyx Biotec Limited Open Offer Targets 26% of Share Capital

Onyx Biotec Limited's open offer seeks up to 47,14,372 equity shares, representing 26% of its paid-up equity and voting share capital, and VC Corporate Advisors filed a corrigendum to the letter of offer on November 11, 2026. The filing updates the statutory open-offer documentation available to public shareholders.

What does Onyx Biotec's open offer seek to acquire?

The offer seeks to acquire up to 47,14,372 fully paid-up equity shares of Onyx Biotec, each with a face value of Rs 10. This quantity represents 26.00% of the target company's total paid-up equity and voting share capital, according to the offer-opening announcement and corrigendum.

VC Corporate Advisors Private Limited issued the document as manager to the offer on behalf of four acquirers: Kunal Bhardwaj, Gautam Bhardwaj, Kanhaiya Bhardwaj and Kapil Bhardwaj. The offer is being conducted under Regulation 18(7) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

The November 11 NSE filing states that VC Corporate Advisors submitted a corrigendum to the letter of offer for the attention of Onyx Biotec's public shareholders. The supplied filing extract does not specify an offer price or disclose post-transaction shareholding figures.

When did the Onyx Biotec open-offer process unfold?

The open-offer process began with a public announcement on July 24, 2026, followed by a corrigendum to that announcement on July 30 and a detailed public statement on July 31. The sequence then moved through the draft letter of offer and letter-of-offer stages before the offer-opening communication.

The exchange information identifies October 13 to October 27, 2026 as the issue period. Separately, the offer documentation refers to an opening public announcement to be published on October 12, 2026. These dates indicate that the opening announcement preceded the stated tender period.

The company page also lists a recommendation of the committee of independent directors dated October 7, 2026. Such a recommendation forms part of the open-offer process and gives public shareholders an independent-director view on the offer documentation. The provided material does not include the committee's recommendation or its reasoning.

Why was a corrigendum filed to the letter of offer?

The November 11 filing was made to communicate a corrigendum to the letter of offer, which is a core document for shareholders considering participation in an open offer. The filing itself describes the corrigendum as being for the attention of public shareholders of Onyx Biotec.

The offer-opening advertisement says it should be read along with the July 24 public announcement, the July 30 corrigendum, the July 31 detailed public statement, the August 7 draft letter of offer and the September 28 letter of offer. This links the latest disclosure to the wider set of transaction documents rather than presenting it as a standalone announcement.

The supplied text also contains references to legal transfer and duplicate share-certificate loss notices, including a seven-day period for claims concerning duplicate share requests. However, the filing extract does not establish that these notices change the number of shares sought in the open offer. The stated acquisition size remains 47,14,372 shares, or 26%.

What does the offer mean for Onyx Biotec shareholders and investors?

For public shareholders, the key immediate point is that the offer documentation has been corrected while the disclosed offer size remains 26% of the company's paid-up equity and voting capital. Shareholders assessing the process would need to rely on the letter of offer, its corrigendum and related statutory disclosures for the applicable terms.

The data provided places promoter holding in Onyx Biotec at 65.1% as of March 2026. It also reports trailing 12-month revenue of Rs 131 crore and trailing 12-month profit after tax of Rs 5 crore. These operating figures provide financial context, but the filing does not connect them to a revised valuation, offer price or change in company operations.

No share-price movement, market reaction or financial forecast is included in the supplied exchange material. Therefore, the disclosed development should be viewed as a procedural update to an ongoing takeover-regulation process, rather than evidence of a confirmed change in Onyx Biotec's earnings or business outlook.

How does the filing fit into India's takeover rules?

India's takeover rules require an acquirer making an open offer to provide public disclosures and a letter of offer so eligible shareholders can examine the transaction terms. In this case, VC Corporate Advisors is acting as manager to the offer, while the four named Bhardwaj acquirers are identified as the parties on whose behalf the offer is being made.

The filing notes that NSE is the only stock exchange where Onyx Biotec's equity shares are presently listed. The series of announcements, including the public announcement, detailed public statement, draft letter of offer and corrected letter of offer, provides the formal disclosure trail for the transaction.

Conclusion

The November 11 corrigendum keeps focus on an open offer for up to 47,14,372 Onyx Biotec shares, equal to 26% of paid-up equity and voting capital. The filing does not alter that stated size in the information provided, and it does not provide a price, valuation revision or confirmed market impact.

Investors should watch for the corrected letter of offer and any subsequent NSE or SEBI disclosures that clarify the terms affected by the corrigendum. The documented issue period was October 13 to October 27, 2026, while the November filing represents a later update to the offer documentation.